Becton, Dickinson and Company (NYSE:BDX) Issues Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Becton, Dickinson and Company (NYSE:BDX) issued its quarterly earnings data on Thursday. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating the consensus estimate of $2.97 by $0.20, RTT News reports. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The firm had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. During the same quarter last year, the firm earned $2.86 earnings per share. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. Becton, Dickinson and Company updated its FY24 guidance to $12.95-13.15 EPS.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded up $3.09 on Thursday, hitting $236.81. The stock had a trading volume of 1,190,014 shares, compared to its average volume of 1,379,163. Becton, Dickinson and Company has a twelve month low of $229.40 and a twelve month high of $287.32. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The firm’s 50 day moving average price is $238.75 and its 200-day moving average price is $240.71. The company has a market capitalization of $68.41 billion, a price-to-earnings ratio of 55.41, a price-to-earnings-growth ratio of 1.94 and a beta of 0.45.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be paid a $0.95 dividend. The ex-dividend date is Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. Becton, Dickinson and Company’s dividend payout ratio is presently 90.05%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Raymond James raised their price objective on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Barclays raised their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $280.00.

Insider Activity

In other news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.